An open-label phase II trial of erlotinib and bevacizumab in patients with advanced non-small cell lung cancer and activating EGFR mutations
BELIEF: Bevacizumab and ErLotinib In EGFR mut+ NSCLC
The BELIEF trial was designed to assess the long-term outcome of patients with advanced non-squamous NSCLC with activating EGFR mutations (L858R and exon 19 deletion) with or without T790M resistance mutation at diagnosis and treated with the combination of erlotinib and bevacizumab.
The final accrual goal of 109 was reached in October 2014 and the results of the primary analysis were published in Lancet Respiratory Medicine 2017; 5 (5): 435-444.
Trial Scheme